Product Description
For Solid Tumors Harboring NTRK Fusion (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03215511)
Mechanisms of Action: TRK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Denmark, France, Germany, Ireland, Italy, Singapore, Spain, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2017-004246-20 | P1 |
Completed |
Oncology Unspecified |
2023-06-21 |
|
LOXO-EXT-17005 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2022-04-11 |